title: Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients.
abstract: Corticosteroid agents (CA) are widely used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) either as concomitant treatment with active agents such as docetaxel, cabazitaxel and abiraterone or in a palliative setting, predominantly due to their anti-inflammatory activity. However, the chronic use of CA has numerous side effects, especially in case of steroid-induced adrenal insufficiency. Furthermore, the latest clinical and preclinical data demonstrate that CA themselves are likely to promote tumour progression in certain populations of patients with mCRPC. Therefore, the role of CA in advanced disease should be carefully weighed for each patient and their withdrawal should be considered in some patients. This is necessary, especially in clinical trials that need good performance status patients to evaluate the activity and the safety of emerging drugs in mCRPC that do not require the concurrent use of CA. In oncology, there is no consensus on an algorithm of gradual steroid tapering and frequently the approach to this procedure is empirical. An algorithm is presented in this article based on clinical observations. Prospective studies are necessary to evaluate the efficacy and safety of the above-proposed algorithm in metastatic castration-resistant prostate cancer.
authors.affiliation: Medical Oncology Clinic, Jules Bordet Institute, Boulevard de Waterloo 121, 1000, Brussels, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Sideris
authors.affiliation: Urology Department, Jules Bordet Institute, Boulevard de Waterloo 121, 1000, Brussels, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Aoun
authors.affiliation: Medical Oncology Clinic, Jules Bordet Institute, Boulevard de Waterloo 121, 1000, Brussels, Belgium.
authors.forename: C N
authors.initials: CN
authors.lastname: Martinez
authors.affiliation: Medical Oncology Clinic, Jules Bordet Institute, Boulevard de Waterloo 121, 1000, Brussels, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Latifyan
authors.affiliation: Medical Oncology Clinic, Jules Bordet Institute, Boulevard de Waterloo 121, 1000, Brussels, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Awada
authors.affiliation: Endocrinology Department, Jules Bordet Institute, Boulevard de Waterloo 121, 1000, Brussels, Belgium. giuseppe.costante@bordet.be.
authors.forename: G
authors.initials: G
authors.lastname: Costante
authors.affiliation: Medical Oncology Clinic, Jules Bordet Institute, Boulevard de Waterloo 121, 1000, Brussels, Belgium.
authors.forename: T
authors.initials: T
authors.lastname: Gil
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
chemical_list: D000305:Adrenal Cortex Hormones
keywords: Androgen receptor; Corticosteroid tapering; Prostate cancer